Table 2.
Treatments | IC50 | Treatment time (h) | Cell type | References |
---|---|---|---|---|
TMX | 12.59 μM | 48 | MCF-7 | Petinari et al. (2004) |
ND | Vero | |||
TMX | 2.72 μg/mL | 72 | MCF-7 | How et al. (2013) |
TMX | 5.13 μg/mL | 4T1 | ||
TMX-Nanostructured lipid carrier (NLC) | 5.56 μg/mL | MCF-7 | ||
TMX-Nanostructured lipid carrier (NLC) | 5.19 μg/mL | 4T1 | ||
TMX | 2.2 ± 0.029 μg/mL | 72 | Vero | Yusmazura et al. (2017) |
TMX | 1.25 μg/mL | 44 | MCF-7 | Salih et al. (2017) |
TMX | 2.3 μg/mL | Vero | ||
TMX | 4.506 μg/mL | 24 | MCF-7 | Hassan et al. (2018) |
TMX | 8.0 ± 0.7 μM | 24 | MCF-7 | Perry et al. (1995) |